ORPHA:330064
Chronic actinic dermatitis
Also known as: Actinic reticuloid · Chronic photosensitivity dermatitis
Publications
727
85th percentile
Trials
1
Interventional, condition-specific
Researchers
888
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Chronic actinic dermatitis (CAD) is an immunologically mediated photodermatosis usually observed in temperate climates and that typically develops in middle-aged to elderly males. CAD is characterized by eczematous and often lichenified pruritic patches and confluent plaques located predominantly on sun-exposed areas with notable sparing of eyelids, skin folds, and postauricular skin. It is often accompanied by multiple contact allergies and usually occurs in a background of either atopic, contact allergic, or seborrheic dermatitis, although it can occur de novo. Resolution of photosensitivity is reported in up to 50% of individuals after 15 years or more, with contact allergies persisting.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018025
- UMLS:C0282309
Additional Mondo synonyms (2)
actinic reticuloid · chronic photosensitivity dermatitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
727 matched papers (303 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
727
727 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
727 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
303 in the last 10 years · high confidence · 85th percentile (publications denominator)
Phrase hits: 727 · MeSH hits: 0
Who's working on it?
888
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Tu Y10 papers · 2025
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China; Department of Dermatology, The Second People's Hospital of Guiyang, Guizhou, 550000, China.
Papers in Europe PMC - 02He L7 papers · 2025
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China. Electronic address: drheli2662@126.com.
Papers in Europe PMC - 03Lim HW5 papers · 2023
Department of Dermatology, Henry Ford Health System, Detroit, MI, USA.
Papers in Europe PMC - 04Wu W5 papers · 2023
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Papers in Europe PMC - 05Chaiyabutr C4 papers · 2025
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Papers in Europe PMC - 06Huang X4 papers · 2026
Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Papers in Europe PMC - 07Li X4 papers · 2026
Department of Dermatology, People's Hospital of Chuxiong Yi Autonomous Prefecture, Chuxiong, 675000, China.
Papers in Europe PMC - 08Wang L4 papers · 2025
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Papers in Europe PMC - 09Xu D4 papers · 2024
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Papers in Europe PMC - 10Chai Y3 papers · 2023
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
high confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chronic actinic dermatitis" OR "Actinic reticuloid" OR "Chronic photosensitivity dermatitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chronic actinic dermatitis" OR "Actinic reticuloid" OR "Chronic photosensitivity dermatitis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T14:06:33.932Z